Biocept (BIOC – Research Report) received a Buy rating and a $12.00 price target from Brookline Capital Markets analyst Kumaraguru Raja today. The company's shares closed last Wednesday at $1.59. According to TipRanks.com, Raja is a 3-star analyst with an average return of 1.6% and a 32.2% success rate. Raja covers the Healthcare sector, focusing on stocks such as Cyclacel Pharmaceuticals, Caladrius Biosciences, and Outlook Therapeutics. Biocept has an analyst consensus of Moderate Buy, with a price target consensus of $9.50. See the top stocks recommended by analysts >> Based on Biocept's latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $13.
https://www.tipranks.com/news/blurbs/biocept-bioc-receives-a-buy-from-brookline-capital-markets?utm_source=advfn.com&utm_medium=referral
Biocept (NASDAQ:BIOC)
Gráfico Histórico do Ativo
De Jul 2022 até Ago 2022 Click aqui para mais gráficos Biocept.
Biocept (NASDAQ:BIOC)
Gráfico Histórico do Ativo
De Ago 2021 até Ago 2022 Click aqui para mais gráficos Biocept.